Mots-C

Mots-C is a mitochondria-derived peptide (MDP) gaining attention in research circles for its potential roles in metabolism and age-related processes. As an MDP, it is encoded within the mitochondrial genome, unlike most peptides which are encoded in the nuclear genome. The proposed mechanism of action involves influencing metabolic pathways, particularly those related to insulin sensitivity and glucose regulation. While the precise mechanisms are still under investigation, research suggests that Mots-C may interact with cellular signaling pathways to improve metabolic homeostasis.

The current research landscape surrounding Mots-C is active but preliminary. A search of research databases reveals over 200 published papers, with a significant portion focusing on preclinical studies. These studies explore the peptide's effects in various models, including those related to metabolic disorders, neurodegenerative diseases, and even cancer. For instance, a study published in *Molecular Neurobiology* (cited 110 times) investigated the therapeutic effects of Mots-C in a rat model of autism, suggesting a role for the peptide in modulating brain function through pathways involving tetrahydrobiopterin and brain-derived neurotrophic factor. Several review articles, such as those published in *American Journal of Physiology-Lung Cell and Molecular Physiology* (cited 86 times) and *Hepatology Communications* (cited 83 times), highlight the emerging role of MDPs, including Mots-C, in lung and liver diseases, respectively. These reviews emphasize the potential of Mots-C as a therapeutic target for metabolic and inflammatory conditions.

Clinical trials involving Mots-C are relatively limited in number and scope, but are actively recruiting. Available data from clinicaltrials.gov indicates seven registered trials. One Phase 2 trial, sponsored by Hudson Biotech, is currently recruiting participants to evaluate the efficacy of Mots-C in improving insulin sensitivity in adults with prediabetes and overweight/obesity. Several other observational studies are also underway, including a study at the University of Athens examining the relationship between Mots-C levels and cardiovascular outcomes in type 2 diabetics with coronary artery disease. Another trial is investigating the cardiovascular effect of GLP-1 agonists, SGLT2 inhibitors, and their combination, with Mots-C levels being monitored as a potential biomarker. The largest study, a cohort focused on deafness-gene screening, is no longer recruiting, but its data may provide insights into the broader health implications of genetic variations related to mitochondrial function.

The safety profile of Mots-C is still being established. Currently, the FDA adverse event reporting system contains no recorded reports related to Mots-C. However, this lack of reported adverse events should not be interpreted as definitive proof of safety, given the limited clinical use and monitoring of the peptide. The current "Safety Score" of 65.0 reflects this uncertainty, indicating a moderate level of perceived safety based on the available data.

From a regulatory perspective, Mots-C is currently unregulated. It is not FDA-approved for any indication, nor is it banned from compounding. This unregulated status means that the quality, purity, and dosage of Mots-C products available on the market can vary considerably. Consumers should be aware of the potential risks associated with purchasing unregulated substances.

Given its purported benefits in areas such as longevity, body composition, and anti-aging, Mots-C is primarily used by individuals interested in biohacking and performance enhancement. These individuals often seek out peptides and other compounds with the goal of optimizing their health and physical capabilities. However, it is crucial to emphasize that the scientific evidence supporting these uses is still limited, and the long-term effects of Mots-C supplementation are unknown.

The current state of Mots-C research is promising, but further rigorous clinical trials are needed to fully understand its efficacy and safety profile before widespread use can be justified, and regulatory oversight may be warranted as more data becomes available.